Immuno-oncology Begins Here

Developing immuno-oncology therapies for patients in need

The successful development of immuno-oncology medicines has significantly improved the prognosis for many people with cancer.

We are building an immuno-oncology franchise, starting with toripalimab, a differentiated PD-1 inhibitor. We plan to add PD-1 combination therapies, including our clinical-stage anti-TIGIT antibody plus internal preclinical programs.

Dedicated to Improving Patient Lives by Expanding Access to Life-Changing Biologic Medicines

Our approved products span multiple therapeutic areas including oncology, immunology and ophthalmology.